Health Care • Biotechnology: Pharmaceutical Preparations
$1.43 ▼ -0.02
(-1.38%)
MKT CAP: $36.5M • VOL: 72.8K
52W L $1 52W H $2
ROARABLE / RQD
E • 33/100
PIOTROSKI
2 / 9
NNVC // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-06-30 | FY 2024
FILED 2024-06-30 | FY 2023
FILED 2023-06-30 |
|---|---|---|---|
| Revenue (Total Sales) | $0 | $0 | $0 |
| YoY Revenue Growth % | — | — | — |
| Gross Profit | — | — | — |
| Gross Margin % | — | — | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$9.6M | -$8.5M | -$8.9M |
| Operating Margin % | — | — | — |
| Net Income (GAAP) | -$9.5M | -$8.3M | -$8.6M |
| EBITDA (Normalized) | -$9.5M | -$8.4M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$8.5M | -$6.3M | -$5.7M |
| Capital Expenditures (CapEx) | $57.0K | $156.6K | — |
| Free Cash Flow (FCF) | -$8.5M | -$6.5M | -$5.7M |
| FCF Margin % | — | — | — |
| Return on Invested Capital (ROIC %) | -45.0% | -45.0% | — |
| Cash & Short-Term Equivalents | $5.2M | $4.0M | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | $11.1M | $10.4M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR NNVC.